Ayala Pharmaceuticals, Inc. (ADXS)
- Previous Close
0.5500 - Open
0.5500 - Bid --
- Ask --
- Day's Range
0.5500 - 0.5550 - 52 Week Range
0.5000 - 1.9500 - Volume
559 - Avg. Volume
21,979 - Market Cap (intraday)
23.64M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-2.5100 - Earnings Date May 21, 2024 - May 27, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.
www.ayalapharma.comRecent News: ADXS
Performance Overview: ADXS
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ADXS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ADXS
Valuation Measures
Market Cap
23.64M
Enterprise Value
27.07M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
256.97
Price/Book (mrq)
--
Enterprise Value/Revenue
2.08k
Enterprise Value/EBITDA
-0.75
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
--
Diluted EPS (ttm)
-2.5100
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--